ARCH THERAPEUTICS, INC.: 10-Q filed 2023-05-23
What ARCH THERAPEUTICS, INC. reported in its quarterly report filed 2023-05-23 (fiscal Q2 2023): 29 published measures, 82 facts as tagged in accession 0001437749-23-015498.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2023-05-23
- Fiscal period
- fiscal Q2 2023
- Accession
- 0001437749-23-015498 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ARCH THERAPEUTICS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 1,592,729 | USD | |
| At 2022-09-30 | 2,603,739 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 7,978,817 | USD | |
| At 2022-09-30 | 6,796,542 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | -6,386,088 | USD | |
| At 2022-12-31 | -5,888,833 | USD | |
| At 2022-09-30 | -4,192,803 | USD | |
| At 2022-03-31 | -3,059,424 | USD | |
| At 2021-12-31 | -2,423,678 | USD | |
| At 2021-09-30 | -1,025,674 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | -902,477 | USD | 90 |
| 2022-10-01 to 2023-03-31 | -2,702,533 | USD | 182 |
| 2022-01-01 to 2022-03-31 | -790,318 | USD | 90 |
| 2021-10-01 to 2022-03-31 | -2,340,465 | USD | 182 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-10-01 to 2023-03-31 | -1,249,931 | USD | 182 |
| 2021-10-01 to 2022-03-31 | -2,212,234 | USD | 182 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | 16,654 | USD | 90 |
| 2022-10-01 to 2023-03-31 | 22,914 | USD | 182 |
| 2022-01-01 to 2022-03-31 | 3,130 | USD | 90 |
| 2021-10-01 to 2022-03-31 | 7,826 | USD | 182 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-10-01 to 2023-03-31 | 532,486 | USD | 182 |
| 2021-10-01 to 2022-03-31 | 0 | USD | 182 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | -57,775,306 | USD | |
| At 2022-09-30 | -55,072,773 | USD |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | -0.71 | USD/shares | 90 |
| 2022-10-01 to 2023-03-31 | -2.15 | USD/shares | 182 |
| 2022-01-01 to 2022-03-31 | -0.67 | USD/shares | 90 |
| 2021-10-01 to 2022-03-31 | -1.98 | USD/shares | 182 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 1,001 | USD | |
| At 2022-09-30 | 2,044 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-10-01 to 2023-03-31 | 172,550 | USD | 182 |
| 2021-10-01 to 2022-03-31 | 306,715 | USD | 182 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | -1,425,484 | USD | 90 |
| 2022-10-01 to 2023-03-31 | -2,701,227 | USD | 182 |
| 2022-01-01 to 2022-03-31 | -1,750,866 | USD | 90 |
| 2021-10-01 to 2022-03-31 | -3,260,684 | USD | 182 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 1,588,228 | USD | |
| At 2022-09-30 | 2,598,195 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | 635,190 | USD | 90 |
| 2022-10-01 to 2023-03-31 | 1,159,503 | USD | 182 |
| 2022-01-01 to 2022-03-31 | 39,452 | USD | 90 |
| 2021-10-01 to 2022-03-31 | 79,781 | USD | 182 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 7,978,817 | USD | |
| At 2022-09-30 | 3,320,494 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 2,425,894 | USD | |
| At 2022-09-30 | 1,328,000 | USD |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 1,402,384 | USD | |
| At 2022-09-30 | 1,414,848 | USD |
Cost of revenue
Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | 18,718 | USD | 90 |
| 2022-10-01 to 2023-03-31 | 36,353 | USD | 182 |
| 2022-01-01 to 2022-03-31 | 17,430 | USD | 90 |
| 2021-10-01 to 2022-03-31 | 34,223 | USD | 182 |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | 1,252,786 | USD | 90 |
| 2022-10-01 to 2023-03-31 | 2,355,701 | USD | 182 |
| 2022-01-01 to 2022-03-31 | 1,208,910 | USD | 90 |
| 2021-10-01 to 2022-03-31 | 2,472,013 | USD | 182 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | 170,634 | USD | 90 |
| 2022-10-01 to 2023-03-31 | 332,087 | USD | 182 |
| 2022-01-01 to 2022-03-31 | 527,656 | USD | 90 |
| 2021-10-01 to 2022-03-31 | 762,274 | USD | 182 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 1,274,605 | shares | |
| At 2022-09-30 | 1,249,432 | shares |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 33,756 | USD | |
| At 2022-09-30 | 33,756 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 32,755 | USD | |
| At 2022-09-30 | 31,712 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 3,500 | USD | |
| At 2022-09-30 | 3,500 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 156,349 | USD | |
| At 2022-09-30 | 436,407 | USD |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | 380 | USD | 90 |
| 2022-10-01 to 2023-03-31 | 1,043 | USD | 182 |
| 2022-01-01 to 2022-03-31 | 799 | USD | 90 |
| 2021-10-01 to 2022-03-31 | 1,598 | USD | 182 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | 523,007 | USD | 90 |
| 2022-10-01 to 2023-03-31 | -1,306 | USD | 182 |
| 2022-01-01 to 2022-03-31 | 960,548 | USD | 90 |
| 2021-10-01 to 2022-03-31 | 920,219 | USD | 182 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-10-01 to 2023-03-31 | -12,464 | USD | 182 |
| 2021-10-01 to 2022-03-31 | 351,876 | USD | 182 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-10-01 to 2023-03-31 | 1,097,894 | USD | 182 |
| 2021-10-01 to 2022-03-31 | 879,995 | USD | 182 |
Inspect the source
- Entity
- ARCH THERAPEUTICS, INC. / CIK 0001537561
- Captured
- SEC response SHA-256
63d0e84748ee59ab7c6817be68d0a32b23d83273213bc50081bb86253a1d4cc2
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001537561.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))